Although the field has yet to find a pivotal drug target from genetic studies, as has occurred for the PCSK9 gene in CVD treatment, insights from recent efforts provide promising paths forward that could result in substantial public health gains for global communities increasingly affected by obesity and its sequelae. Here, PCSK9 is linked to obesity due to melanocortin 4 receptor deficiency.